HMMJ-U:CA:TSX-Horizons Marijuana Life Sciences Index ETF (USD)

ETF | Others |

Last Closing

CAD 8.36

Change

0.00 (0.00)%

Market Cap

CAD 0.09B

Volume

100.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-04 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XEF-U:CA iShares Core MSCI EAFE IMI Ind..

-0.46 (-1.63%)

CAD 6.19B
CASH:CA GLOBAL X HIGH INTEREST SAVINGS..

N/A

CAD 4.84B
PHYS-U:CA Sprott Physical Gold Trust

-0.38 (-2.06%)

CAD 4.76B
XUS-U:CA iShares Core S&P 500 Index ETF

-0.51 (-0.76%)

CAD 4.54B
HXT-U:CA Horizons S&P/TSX 60 Index ETF

+0.21 (+0.50%)

CAD 3.92B
CEF-U:CA Sprott Physical Gold and Silve..

-0.43 (-1.89%)

CAD 3.78B
XEQT:CA iShares Core Equity Portfolio

-0.14 (-0.45%)

CAD 3.54B
PSLV-U:CA Sprott Physical Silver Trust

-0.20 (-1.90%)

CAD 3.29B
NSCB:CA NBI Sustainable Canadian Bond ..

-0.05 (-0.23%)

CAD 2.78B
NUBF:CA NBI Unconstrained Fixed Income..

-0.20 (-0.94%)

CAD 2.52B

ETFs Containing HMMJ-U:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.60% 95% A 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.60% 95% A 87% B+
Trailing 12 Months  
Capital Gain 17.91% 75% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.91% 75% C 73% C
Trailing 5 Years  
Capital Gain -45.25% 2% F 12% F
Dividend Return 1.31% 63% D 7% C-
Total Return -43.94% 2% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain 14.55% 96% N/A 84% B
Dividend Return 14.59% 97% N/A 82% B
Total Return 0.05% 49% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 65.47% 2% F 12% F
Risk Adjusted Return 22.29% 62% D 51% F
Market Capitalization 0.09B 64% D 35% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.